KROS

Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing novel therapeutics to treat a range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (TGF-B), family of proteins. Its lead product candidate, KER-050, is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, and in patients with myelofibrosis. Its product candidate, KER-012, is being developed for the treatment of pulmonary arterial hypertension, or PAH, and for the treatment of cardiovascular disorders. Its product candidate, KER-065, is being developed for the treatment of obesity and for the treatment of neuromuscular diseases. KER-050 is designed to raise red blood cell and platelet production by inhibiting the signaling of a subset of the TGF-B family of proteins to promote hematopoiesis.

Wall Street analysts forecast KROS stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for KROS is 20.80 USD with a low forecast of 16.00 USD and a high forecast of 27.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Keros Therapeutics Inc revenue for the last quarter amounts to 14.26M USD, increased 3575.77 % YoY.

Keros Therapeutics Inc. EPS for the last quarter amounts to -0.18 USD, decreased -87.23 % YoY.

Keros Therapeutics Inc (KROS) has 169 emplpoyees as of December 15 2025.

Today KROS has the market capitalization of 655.33M USD.